RFP
GMAB icon

Root Financial Partners’s Genmab GMAB Stock Holding History

Root Financial Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$805 – 1528
2026
Q1 		$805 Buy
30
+8
+36% +$240 ﹤0.01% 2683
2025
Q4 		$678 Buy
22
+17
+340% +$530 ﹤0.01% 2171
2025
Q3 		$153 Buy
+5
New +$122 ﹤0.01% 2220

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Root Financial Partners's GMAB Position: Q2 2026 in Review

Root Financial Partners sold out of Genmab (GMAB) in Q2 2026, closing a stake of 30 shares — an estimated $805 sold.

Root Financial Partners first reported a position in GMAB in Q3 2025 and held it in 3 quarters. The position peaked at $805 in Q1 2026. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Root Financial Partners reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 30 Genmab shares in Q2 2026, an estimated $805.
  • Root Financial Partners first reported a position in Genmab in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's Genmab position peaked at $805 in Q1 2026.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.